Skip to content

About Us
Our Science
Partnerships
News

News
READ THE LATEST UPDATES

July 1, 2025 | Press Releases

Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis

April 24, 2025 | Press Releases

Inmagene Reports Topline Results from Phase 2a Study of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, in Patients with Alopecia Areata

January 9, 2025 | Press Releases

Inmagene Reports Positive Topline Results of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Atopic Dermatitis

2

About Us
Our Science
Partnerships
News

About Us
Our Science
Partnerships
News

Copyright © 2025 Miragene All Rights Reserved

Company

About Us
Our Science
Pipeline
Partnerships
Contact Us

Scroll to Top